July 27, 2018

Glycanostics wins the European Research Council Grant

Glycanostics innovations are again supported and highly ranked by leading industry experts. This time the company won the European Research Council (ERC) Proof of Concept Grant. The ERC president Jean Pierre Bourguignon mentioned that their Pannel recommended Glycanostics proposal for funding at the sufficiently high position in the rank list. He is confident that the grant will help to further explore and develop the innovation potential of Glycanostycs projects. 

"This ERC grant is another important step towards the development of the diagnostic kits by our company. We are going to complete clinical validation in collaboration with Innsbruck biobank and by cooperation with Professor Helmut Klocker (University Clinic for Urology, Medical University Innsbruck), to prepare for the certification process and to get in contact with key opinion leaders in the EU. Also, in the future, we would like to develop kits to diagnose other diseases, such as breast cancer."

Comments Jan Tkac, co-founder and executive manager of Glycanostics Ltd.

The media has already called the latest Glycanostics success an 'European Scientific Oscar', showing great interest in the project. The company's innovations are also supported by Pavol Čekan (CEO of Multiplex DX), the Ministry of Health of the Slovak Republic and the Slovak Academy of Sciences (SAS), which reflects the long-term strategy of the development of biomedical applied research in Slovakia.

European Research Council / Proof of Concept Grant

Other News

June 22, 2021

Glycanostics meet the President of the EC Mrs. Ursula von der Leyen

On Monday, June, 21st our CEO Eva Kovacova (on the right) together with CSO Jan Tkac (on the left) had a great honour to introduce the company Glycanostics to the President of the EC Mrs. Ursula von der Leyen, our Prime Minister Mr. Eduard Heger and Vice-President of the EC Mr. Maros Sefcovic. As one out of seven selected innovative companies, we presented our highly accurate, non-invasive, and early-stage cancer diagnostics that can help save the lives of millions of people worldwide.

October 18, 2019

A highly-prestigious award for a Glycanostics co-founder

ESET launched a prestigious ESET Science Award for exceptional scientists

October 3, 2019

International Patent Application No. PCT/EP2019/057386

Means and methods for glycoprofiling of a protein

August 31, 2019

Glycanostics succesfully finished Horizon 2020 SME Instrument 1 Grant

Glycanostics successfully finished the first phase of SME Instrument

December 10, 2018

Glycanostics Wins Horizon 2020 Grant

After receiving the prestigious “Seal of Excellence” on October 23, the next submission to the Horizon 2020 Programme, won a € 50 000 grant.

October 27, 2018

Glycanostics Receives the Prestigious Horizon 2020 “Seal of Excellence”

This project received the highest scores for its proposal in the extremely competitive evaluation process.

October 24, 2018

Glycanostics Wins TOP-6 Best Startups in Central Europe

Glycanostics was chosen as a finalist in the Grand Finale with five other remarkable startups.

August 14, 2018

Glycanostics Applies for Innovation-Securing Patent

The application covering Glycanostics' diagnostic method is currently filed in two patent offices in Europe and Luxemburg.

June 14, 2018

Glycanostics Takes 3rd Place in Vodafone’s Idea of The Year Competition

The competition's objectives are to actively support innovative projects with high market potential

May 1, 2018

Glycanostics PCa DX kit showed 95+% accuracy on the pre-clinical validation

In April 2018 the technology validation was successfully completed indicating a great potential of Glycanostics innovative products for prostate cancer (PCa) diagnostics.

November 30, 2017

Jan Tkac and Tomas Bertok – Scientists of the year award winners - establish Glycanostics to bring their revolutionary innovation to cancer diagnostics market

Glycanostics is an innovative start-up company established in 2017 to bring its revolutionary cancer diagnostics products to the US and EU markets.